In a prospective evaluation including 20 eyes, a trifocal toric IOL effectively reduced astigmatism, had good postoperative rotational stability, provided a full range of excellent uncorrected visual acuity with good contrast sensitivity, caused no significant phoic phenomena, and was associated with high patient satisfaction.
This article was reviewed by Yonca A. Akova
Findings from a study evaluating postoperative clinical and quality of life outcomes show that an aspheric, nonapodized trifocal toric IOL (AcrySof IQ PanOptix Toric IOL, Alcon) was associated with excellent visual and refractive results, leading to high spectacle independence and patient satisfaction, according to Yonca A. Akova, MD.
“Untreated preexisting corneal astigmatism is an important limiting factor for visual outcomes with multifocal IOL implantation,” said Dr. Akova, professor of ophthalmology, Bayindir Hospital, Ankara, Turkey.
Dr. Akova noted that the study could be among the first reporting clinical outcomes with the toric version of this trifocal IOL.
“The results of this investigation show that the IOL effectively reduced astigmatism, had good rotational stability, and provided excellent visual outcomes at all distances to provide excellent patient satisfaction,” she said.
The trifocal toric IOL has a central trifocal zone of 4.5 mm and 15 diffractive rings. It features a +3.25 D add for near focus and a +2.17 D add for the intermediate focal point (60 cm).
This new trifocal toric IOL technology has brought the intermediate focal point from 80 cm to 60 cm, which aims to provide comfortable vision in daily life.
Dr. Akova conducted the noncomparative study evaluating the trifocal toric IOL with Oya Donmez, MD, ophthalmologist, Bayindir Hospital. It included 20 eyes of 15 patients operated on between April 2018 and June 2018. Eyes were selected for implantation of the toric version of the trifocal IOL based on having ≥1.25 D of with-the-rule astigmatism or ≥0.75 D of against-the-rule astigmatism.